A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2017
Price : $35 *
At a glance
- Drugs Spanlecortemlocel (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 13 Oct 2016 Status changed from suspended to completed.
- 06 Sep 2016 Status changed from recruiting to suspended.